Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

ABSTRACT Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients. In this study, we performed a high-throughput screening of 3,731 characterized compounds and identi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marion Gruffaz, Shenghua Zhou, Karthik Vasan, Teresa Rushing, Qing Liu Michael, Chu Lu, Jae U. Jung, Shou-Jiang Gao
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	cytarabine DNA/RNA syntheses inhibition of latent and lytic replication KSHV latency-associated nuclear antigen (LANA) degradation primary effusion lymphoma Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/813532cf3c73482aa2786bdbec28fc9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:813532cf3c73482aa2786bdbec28fc9f
record_format	dspace
spelling	oai:doaj.org-article:813532cf3c73482aa2786bdbec28fc9f2021-11-15T16:00:24ZRepurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications10.1128/mBio.00756-182150-7511https://doaj.org/article/813532cf3c73482aa2786bdbec28fc9f2018-07-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00756-18https://doaj.org/toc/2150-7511ABSTRACT Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients. In this study, we performed a high-throughput screening of 3,731 characterized compounds and identified cytarabine, approved by the FDA for treating numerous types of cancer, as a potent inhibitor of KSHV-induced PEL. We showed the high efficacy of cytarabine in the growth inhibition of various PEL cells by inducing cell cycle arrest and apoptosis. Cytarabine inhibited host DNA and RNA syntheses and therefore induced cellular cytotoxicity. Furthermore, cytarabine inhibited viral DNA and RNA syntheses and induced the rapid degradation of KSHV major latent protein LANA (latency-associated nuclear antigen), leading to the suppression of KSHV latent replication. Importantly, cytarabine effectively inhibited active KSHV replication and virion production in PEL cells. Finally, cytarabine treatments not only effectively inhibited the initiation and progression of PEL tumors but also induced regression of grown PEL tumors in a xenograft mouse model. Altogether, our study has identified cytarabine as a novel therapeutic agent for treating PEL as well as eliminating KSHV persistent infection. IMPORTANCE Primary effusion lymphoma is an aggressive malignancy caused by Kaposi’s sarcoma-associated herpesvirus. The outcome of primary effusion lymphoma is dismal without specific treatment. Through a high-throughput screening of characterized compounds, we identified an FDA-approved compound, cytarabine, as a potent inhibitor of primary effusion lymphoma. We showed that cytarabine induced regression of PEL tumors in a xenograft mouse model. Cytarabine inhibited host and viral DNA and RNA syntheses, resulting in the induction of cytotoxicity. Of interest, cytarabine induced the degradation of KSHV major latent protein LANA, hence suppressing KSHV latent replication, which is required for PEL cell survival. Furthermore, cytarabine inhibited KSHV lytic replication program, preventing virion production. Our findings identified cytarabine as a novel therapeutic agent for treating PEL as well as for eliminating KSHV persistent infection. Since cytarabine is already approved by the FDA, it might be an ideal candidate for repurposing for PEL therapy and for further evaluation in advanced clinical trials.Marion GruffazShenghua ZhouKarthik VasanTeresa RushingQing Liu MichaelChu LuJae U. JungShou-Jiang GaoAmerican Society for MicrobiologyarticlecytarabineDNA/RNA synthesesinhibition of latent and lytic replicationKSHVlatency-associated nuclear antigen (LANA) degradationprimary effusion lymphomaMicrobiologyQR1-502ENmBio, Vol 9, Iss 3 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	cytarabine DNA/RNA syntheses inhibition of latent and lytic replication KSHV latency-associated nuclear antigen (LANA) degradation primary effusion lymphoma Microbiology QR1-502
spellingShingle	cytarabine DNA/RNA syntheses inhibition of latent and lytic replication KSHV latency-associated nuclear antigen (LANA) degradation primary effusion lymphoma Microbiology QR1-502 Marion Gruffaz Shenghua Zhou Karthik Vasan Teresa Rushing Qing Liu Michael Chu Lu Jae U. Jung Shou-Jiang Gao Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
description	ABSTRACT Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients. In this study, we performed a high-throughput screening of 3,731 characterized compounds and identified cytarabine, approved by the FDA for treating numerous types of cancer, as a potent inhibitor of KSHV-induced PEL. We showed the high efficacy of cytarabine in the growth inhibition of various PEL cells by inducing cell cycle arrest and apoptosis. Cytarabine inhibited host DNA and RNA syntheses and therefore induced cellular cytotoxicity. Furthermore, cytarabine inhibited viral DNA and RNA syntheses and induced the rapid degradation of KSHV major latent protein LANA (latency-associated nuclear antigen), leading to the suppression of KSHV latent replication. Importantly, cytarabine effectively inhibited active KSHV replication and virion production in PEL cells. Finally, cytarabine treatments not only effectively inhibited the initiation and progression of PEL tumors but also induced regression of grown PEL tumors in a xenograft mouse model. Altogether, our study has identified cytarabine as a novel therapeutic agent for treating PEL as well as eliminating KSHV persistent infection. IMPORTANCE Primary effusion lymphoma is an aggressive malignancy caused by Kaposi’s sarcoma-associated herpesvirus. The outcome of primary effusion lymphoma is dismal without specific treatment. Through a high-throughput screening of characterized compounds, we identified an FDA-approved compound, cytarabine, as a potent inhibitor of primary effusion lymphoma. We showed that cytarabine induced regression of PEL tumors in a xenograft mouse model. Cytarabine inhibited host and viral DNA and RNA syntheses, resulting in the induction of cytotoxicity. Of interest, cytarabine induced the degradation of KSHV major latent protein LANA, hence suppressing KSHV latent replication, which is required for PEL cell survival. Furthermore, cytarabine inhibited KSHV lytic replication program, preventing virion production. Our findings identified cytarabine as a novel therapeutic agent for treating PEL as well as for eliminating KSHV persistent infection. Since cytarabine is already approved by the FDA, it might be an ideal candidate for repurposing for PEL therapy and for further evaluation in advanced clinical trials.
format	article
author	Marion Gruffaz Shenghua Zhou Karthik Vasan Teresa Rushing Qing Liu Michael Chu Lu Jae U. Jung Shou-Jiang Gao
author_facet	Marion Gruffaz Shenghua Zhou Karthik Vasan Teresa Rushing Qing Liu Michael Chu Lu Jae U. Jung Shou-Jiang Gao
author_sort	Marion Gruffaz
title	Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
title_short	Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
title_full	Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
title_fullStr	Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
title_full_unstemmed	Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications
title_sort	repurposing cytarabine for treating primary effusion lymphoma by targeting kaposi’s sarcoma-associated herpesvirus latent and lytic replications
publisher	American Society for Microbiology
publishDate	2018
url	https://doaj.org/article/813532cf3c73482aa2786bdbec28fc9f
work_keys_str_mv	AT mariongruffaz repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT shenghuazhou repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT karthikvasan repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT teresarushing repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT qingliumichael repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT chulu repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT jaeujung repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications AT shoujianggao repurposingcytarabinefortreatingprimaryeffusionlymphomabytargetingkaposissarcomaassociatedherpesviruslatentandlyticreplications
_version_	1718426978318548992

Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

Ejemplares similares